Pipeline

Xeris is interested in establishing a portfolio of strategic collaborations with key partners who wish to co-develop products using Xeris’ platform technologies (XeriSol^® and XeriJect^®). Currently, Xeris is working on a number of formulation feasibility programs for its own, such as XP-8121 for hypothyroidism, as well as its partners’ pipeline in the areas of small molecules, peptides, biologics, and monoclonal antibodies. We welcome the opportunity to discuss areas of potential common interest upon which to build value for both parties. To discuss partnering opportunities, please contact us.